NCT07096713View on ClinicalTrials.gov

Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema

NACompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2024

Conditions
Anti-VEGF Therapy
Interventions
DRUG

Intervention 1: Brolucizumab

Intravitreal injection of Brolucizumab (6 mg/0.05 mL) for the treatment of center-involving diabetic macular edema.

DRUG

Intervention 2: Aflibercept

Intravitreal injection of Aflibercept (2 mg/0.05 mL) for the treatment of center-involving diabetic macular edema.

Trial Locations (1)

13111

Benha University, Banha

All Listed Sponsors
lead

Benha University

OTHER

NCT07096713 - Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema | Biotech Hunter | Biotech Hunter